Page 163 - 2020_09-Haematologica-web
P. 163
Mutated factor X to correct hemophilias
C
E
G
haematologica | 2020; 105(9)
2341
AB
D
F
Figure 6. Evaluation of actiten potency in several factor-deficient or hemo- philia plasma samples. Each plasma sample was activated by 0.5 pM tis- sue factor and 4 μM phospholipids. For all panels, the following representa- tions are used: normal plasma (●), deficient plasma (○). (A) Actiten potency was evaluated at different concentrations (10→120 μg/mL) in factor VIII (FVIII)-deficient plasma (blue ●). (B) Actiten potency was evaluated at 10 or 20 μg/mL (blue ●, ▲, respectively) in hemophilia A plasma. (C) Actiten potency was evaluated at different concentrations (10→30 μg/mL, blue ●, ▲, ■, respectively) in hemophilia A plasma with 292 BU/mL. (D) Actiten potency was evaluated at 10 and 20 μg/mL (blue ●, ▲, respectively) in fac- tor IX (FIX)-deficient plasma. (E) Actiten potency was evaluated at 10 and 20 μg/mL (blue ●, ▲, respectively) in FIX-deficient plasma with spiked anti-FIX inhibitors (17 BU/mL). (F) Actiten potency was evaluated at 10 and 20 μg/mL (blue ●, ▲, respectively) in factor X (FX)-deficient plasma. (G) Actiten potency was evaluated at 10 and 20 μg/mL (blue ●, ▲, respectively) in fac- tor XI (FXI)-deficient plasma. The data are derived from duplicate evalua- tions and are representative of 2-13 independent assays.
